UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 13, 2006
EPIX Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| |
|
|
| 000-21863
|
|
04-3030815 |
| |
| (Commission File Number)
|
|
(IRS Employer Identification No.) |
| |
|
|
161 First Street, Cambridge, Massachusetts 02142
|
| |
| (Address of Principal Executive Offices)
|
|
(Zip Code) |
(617) 250-6000
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
þ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 8.01. Other Events.
On July 13, 2006, EPIX Pharmaceuticals, Inc. (the “Company”) issued a press release announcing
that Schering AG has decided not to exercise its option for the Company’s fibrin-binding imaging
agent EP-2104R. Under the terms of the Company’s agreement with Schering AG, the Company will
retain full rights to the EP-2104R program. The Company intends to pursue a collaboration for the
continued development of EP-2104R with other potential partners. A copy of the press release is
attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
| (d) |
|
The following exhibits are furnished with this report: |
| |
|
|
| Exhibit Number |
|
Description |
| 99.1
|
|
Press Release dated July 13, 2006 |